Advids launches healthcare video solution for HealthTech, MedDevice and life sciences

Advids has introduced a dedicated video production offering for HealthTech, MedDevice and life sciences companies as AI, new buying models and stricter ad rules reshape healthcare marketing. The company says the solution is built to help brands explain complex science to both clinical buyers and consumers without losing accuracy or compliance.

Why it matters: - Healthcare companies now have to sell to two very different audiences at once: clinical buying committees and consumer-facing audiences. - Advids is positioning video as a way to close what it calls the Explanation Gap between complex science and fast approval cycles. - The shift matters because a video that is scientifically outdated can become a compliance risk, not just a weak marketing asset.

What happened: - Advids launched a dedicated video production solution for HealthTech, MedDevice and life sciences companies. - The launch comes as U.S. digital health startups raised $14.2 billion in 2025, up 35% year over year, according to Rock Health. - The global digital health ecosystem now includes more than 118,000 companies, per StartUs Insights. - Advids said the new offering formalizes work it has already done across healthcare. - The agency says it has visualized more than 240 healthcare innovations. - Advids has produced videos for more than 230 healthcare companies across digital care, precision oncology, research reagents and analytical instrumentation. - Client work has included DISPENDIX in laboratory automation, NextGen in health IT and Surgentec in surgical devices. - Advids holds a 5.0 rating on Clutch and a 4.7 rating on G2 across its broader video work.

The details: - Healthcare technology sales cycles often run 12 to 18 months and involve buying committees of 8 to 12 stakeholders across clinical, IT, compliance and finance. - Each stakeholder looks for a different proof point, from clinical evidence to integration, security and total cost of ownership. - Advids says that creates an Explanation Gap between what a technology does and what a buyer can verify quickly enough to approve. - In MedTech, the AI-based surgical robotics market is projected to grow from $7.96 billion in 2025 to $17.35 billion by 2030, according to The Business Research Company. - AI in medical devices overall is projected to grow from $12.38 billion to $42.43 billion over the same period, according to the same source. - IQVIA identifies AI, real-world evidence, interoperability, FDA regulatory shifts and surgical robotics as defining MedTech trends for 2026. - In life sciences, Deloitte's 2026 Life Sciences Outlook found 48% of companies reporting accelerated digital transformation and 41% naming generative AI as an influential trend. - Analysts are describing a shift from wet-lab experimentation toward AI-driven computational discovery. - Amgen, Genentech and Boehringer Ingelheim have each launched direct-to-patient programs offering self-pay access to certain medications. - Global healthcare e-commerce is projected to reach $614 billion in 2026, per EY. - Subscription and membership care is growing about 10% annually. - A 2026 Tebra survey found 48% of U.S. consumers interested in subscription-based healthcare and 21% willing to pay $100 or more per month for unlimited primary care. - Out-of-pocket healthcare spending is projected to reach $800 billion this year. - Google restricts advertising for prescription-requiring device categories. - Meta prohibits ads that assert or imply a viewer's health condition. - Healthcare-specific programmatic platforms including DeepIntent and PulsePoint now offer clinician-level targeting that general ad networks do not support. - BCG says trust is the foundational requirement for direct-to-patient models. - Hospitals and health systems rank as the most trusted providers of subscription health services at 45%, ahead of every technology brand measured. - Advids says the solution is built around three use cases: health system procurement, key opinion leader enablement and consumer awareness. - Health system procurement work is designed for enterprise hospital adoption and months of committee review. - Key opinion leader enablement uses educational motion graphics to explain mechanism of action, device placement, molecular pathway and surgical workflow. - Consumer awareness work is built separately for feed and streaming environments. - The company says its production process follows four steps: Ingest, Architect, Visualize and Deploy. - The process pairs clinical data and commercial strategy review with patient-outcome narrative mapping and high-fidelity motion graphics under strict QA. - Advids also built an Adaptive Architecture process that updates visual layers as science, trial data or regulatory labels change. - The company uses layered video production techniques to make those updates without rebuilding from scratch.

Between the lines: - The launch reflects a broader convergence in healthcare marketing, where the same asset must satisfy regulators, clinicians and consumers. - AI is changing both the science and the sales motion, which raises the bar for accuracy and speed in marketing production. - The move also suggests generic creative teams may struggle in categories where claims, targeting rules and approval cycles are unusually constrained. - Avilash Behera, founder of Advids, said the job description for healthcare marketers has changed and is no longer just a bigger version of the old one.

What's next: - Advids is likely to push more healthcare brands toward tailored video systems rather than one-off campaign assets. - The company says the solution will be used where science changes after launch and content must be updated to stay compliant. - As direct-to-patient models, subscription care and AI-driven discovery expand, healthcare marketing teams will need faster ways to adapt evidence into usable creative.

The bottom line: - Advids is betting that healthcare video now has to do more than explain a product. It has to translate shifting science into content that can pass clinical scrutiny, ad restrictions and consumer attention tests at the same time.